Cerus Corp. (CERS) Monday announced 15 percent increase in preliminary full year product revenue from the prior year and that exceeded its prior guidance. The company expects 8-11 percent growth in 2025 product revenues.
Full-Year 2024 product revenues is expected to be $180.3 million, while its product revenue guidance was in a range of $177-$179 million. The company said its product revenue growth was driven by sustained momentum across our Intercept platelet franchise.
The 2025 product revenues is projected to be between $194-$200 million, and year-over-year product revenue growth for the first quarter of 2025 is expected to be approximately 10 to 15 percent over the first quarter of 2024.
For comments and feedback: editorial@rttnews.com